Status:
COMPLETED
A Randomized, Single-blind, Controlled Clinical Study of Cardiomyopeptidin on Improving Ischemia-reperfusion Injury in Patients With Acute ST-segment Elevation Myocardial Infarction After Primary PCI
Lead Sponsor:
Chinese PLA General Hospital
Collaborating Sponsors:
Dalian Zhen-Ao Bio-Tech Co., Ltd.
Conditions:
Cardiovascular Diseases
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
This study aim to investigate the myocardium protection effect of cardiomyopeptidin in patients undergoing primary PCI for ST-elevation myocardial infarction through myocardial enhanced MRI.
Detailed Description
Investigators will enroll 160 patients with STEMI who were admitted to the Chinese PLA General Hospital between March 2022 and Marchr 2024，the investigators randomly assign eligible patients in a 1:1 ...
Eligibility Criteria
Inclusion
- STEMI patients: typical chest pain lasting 30 min within the previous 12 h, a clear ST-segment elevation of N0.1 mV in ≥2 contiguous electrocardiographic leads, and elevated blood levels of troponin T
- patients were scheduled to undergo diagnostic cardiac angiography or percutaneous coronary interventions
Exclusion
- had once treated by ivabradine
- history of myocardial infarction
- mechanical complications
- Unable to perform myocardial MRI
- liver and kidney failure
- malignant tumor
- unconscious
- Patients with other significant abnormal signs, laboratory tests and clinical disease are unsuitable for participation in the study accessed by clinicians.
Key Trial Info
Start Date :
November 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2025
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT06155110
Start Date
November 1 2019
End Date
May 1 2025
Last Update
May 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chinese People's Liberation Army General Hospital
Beijing, Beijing Municipality, China, 100853